137 related articles for article (PubMed ID: 34118694)
1. The new services that opioid treatment programs have adopted in response to COVID-19.
Cantor J; Laurito A
J Subst Abuse Treat; 2021 Nov; 130():108393. PubMed ID: 34118694
[TBL] [Abstract][Full Text] [Related]
2. COVID-19-related policy changes for methadone take-home dosing: A multistate survey of opioid treatment program leadership.
Levander XA; Pytell JD; Stoller KB; Korthuis PT; Chander G
Subst Abus; 2022; 43(1):633-639. PubMed ID: 34666636
[No Abstract] [Full Text] [Related]
3. TIME TO REVISIT UNEVEN POLICY IN THE UNITED STATES FOR MEDICATION FOR OPIOID USE DISORDER DURING COVID-19.
Pena E; Ahmed S
Addiction; 2020 Oct; 115(10):1978-1979. PubMed ID: 32447795
[No Abstract] [Full Text] [Related]
4. Changes in methadone program practices and fatal methadone overdose rates in Connecticut during COVID-19.
Brothers S; Viera A; Heimer R
J Subst Abuse Treat; 2021 Dec; 131():108449. PubMed ID: 34098303
[TBL] [Abstract][Full Text] [Related]
5. Opioid treatment program safety measures during the COVID-19 pandemic: a statewide survey.
Bandara S; Maniates H; Hulsey E; Smith JS; DiDomenico E; Stuart EA; Saloner B; Krawczyk N
BMC Health Serv Res; 2022 Mar; 22(1):418. PubMed ID: 35354460
[TBL] [Abstract][Full Text] [Related]
6. Critical incidents in Colorado's opioid treatment programs: A comparison of the COVID-19 pandemic to previous years.
Bortz C; Armistead I; Bonaguidi A; Coyle DT
J Subst Use Addict Treat; 2024 Jun; 161():209342. PubMed ID: 38513975
[TBL] [Abstract][Full Text] [Related]
7. The impact of COVID-19 on opioid treatment programs in the United States.
Goldsamt LA; Rosenblum A; Appel P; Paris P; Nazia N
Drug Alcohol Depend; 2021 Nov; 228():109049. PubMed ID: 34600258
[TBL] [Abstract][Full Text] [Related]
8. Tailoring services in opioid treatment programs for patients involved in America's criminal justice system: national associations and variation by state and Medicaid expansion status.
Pro G; Montgomery BEE; Zaller N
Subst Abuse Treat Prev Policy; 2021 Jun; 16(1):50. PubMed ID: 34147098
[TBL] [Abstract][Full Text] [Related]
9. Shifting Medication Treatment Practices in the COVID-19 Pandemic: A Statewide Survey of Pennsylvania Opioid Treatment Programs.
Krawczyk N; Maniates H; Hulsey E; Smith JS; DiDomenico E; Stuart EA; Saloner B; Bandara S
J Addict Med; 2022 Nov-Dec 01; 16(6):645-652. PubMed ID: 35165225
[TBL] [Abstract][Full Text] [Related]
10. Impact of COVID-19-related methadone regulatory flexibilities: views of state opioid treatment authorities and program staff.
Mitchell SG; Jester J; Gryczynski J; Whitter M; Fuller D; Halsted C; Schwartz RP
Addict Sci Clin Pract; 2023 Oct; 18(1):61. PubMed ID: 37848970
[TBL] [Abstract][Full Text] [Related]
11. A trial of implementation facilitation to increase timely admission to methadone treatment.
Gryczynski J; Mitchell SG; Whitter M; Fuller D; Mitchell MM; Edelman EJ; Schwartz RP
J Subst Use Addict Treat; 2024 Jul; 162():209375. PubMed ID: 38642889
[TBL] [Abstract][Full Text] [Related]
12. Characteristics and current clinical practices of opioid treatment programs in the United States.
Jones CM; Byrd DJ; Clarke TJ; Campbell TB; Ohuoha C; McCance-Katz EF
Drug Alcohol Depend; 2019 Dec; 205():107616. PubMed ID: 31678836
[TBL] [Abstract][Full Text] [Related]
13. State guidance and system changes related to COVID-19: Impact on opioid treatment programs.
Fuller DB; Gryczynski J; Schwartz RP; Halsted C; Mitchell SG; Whitter M
J Subst Use Addict Treat; 2024 Mar; 158():209214. PubMed ID: 38042301
[TBL] [Abstract][Full Text] [Related]
14. Early Effects of COVID-19 on Programs Providing Medications for Opioid Use Disorder in Jails and Prisons.
Bandara S; Kennedy-Hendricks A; Merritt S; Barry CL; Saloner B
J Addict Med; 2020; 14(5):e257-e260. PubMed ID: 32868681
[TBL] [Abstract][Full Text] [Related]
15. Is necessity also the mother of implementation? COVID-19 and the implementation of evidence-based treatments for opioid use disorders.
Becker SJ; Garner BR; Hartzler BJ
J Subst Abuse Treat; 2021 Mar; 122():108210. PubMed ID: 33509413
[TBL] [Abstract][Full Text] [Related]
16. The COVID-19 pandemic and opioid use disorder: Expanding treatment with buprenorphine, and combining safety precautions with telehealth.
Cales RH; Cales SC; Shreffler J; Huecker MR
J Subst Abuse Treat; 2022 Feb; 133():108543. PubMed ID: 34210567
[TBL] [Abstract][Full Text] [Related]
17. Adoption of methadone take home policy by U.S. state opioid treatment authorities during COVID-19.
Roy V; Buonora M; Simon C; Dooling B; Joudrey P
Int J Drug Policy; 2024 Feb; 124():104302. PubMed ID: 38183861
[TBL] [Abstract][Full Text] [Related]
18. An examination of telehealth policy impacts on initial rural opioid use disorder treatment patterns during the COVID-19 pandemic.
Hughes PM; Verrastro G; Fusco CW; Wilson CG; Ostrach B
J Rural Health; 2021 Jun; 37(3):467-472. PubMed ID: 33720447
[TBL] [Abstract][Full Text] [Related]
19. Telehealth in school-based practice: Perceived viability to bridge global OT practitioner shortages prior to COVID-19 global health emergency.
Abbott-Gaffney C; Jacobs K
Work; 2020; 67(1):29-35. PubMed ID: 32925151
[TBL] [Abstract][Full Text] [Related]
20. COVID-19: A catalyst for change in telehealth service delivery for opioid use disorder management.
Mehtani NJ; Ristau JT; Snyder H; Surlyn C; Eveland J; Smith-Bernardin S; Knight KR
Subst Abus; 2021; 42(2):205-212. PubMed ID: 33684331
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
